# US 2010/0168394 A1 · Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168394 A1
- Document ID: US20100168394A1
- Status: Published application
- Kind: A1
- Application number: 12/410,426
- Filed: 2009-03-24
- Published: 2010-07-01
- Earliest claimed: 2008-08-08
- Assignees: Snu R&Db Foundation
- Inventors: SEONG-HOE PARK; KYEONG-CHEON JUNG; YOUNGMEE BAE; SEONG-PYO PARK; YOON-KYUNG JEON
- Web page: https://patentgrep.com/patent/US20100168394A1

## CPC

- C07K 16/2821: {against ICAM molecules, e.g. CD50, CD54, CD102}
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.

## Claims

### Claim 1

An antibody that competes with an antibody produced by a hybridoma deposited as an accession number of KCLRF-BP-00198 for binding to domain 1 of human intercellular adhesion molecules-1 (ICAM-1).

### Claim 2

An antibody that binds to domain 1 of human ICAM-1 without inhibiting the binding of human ICAM-1 to human leukocyte function antigen-1 (LFA-1).

### Claim 3 (depends on 1)

The antibody according to claim 1, wherein the antibody is in isolated form.

### Claim 4 (depends on 1)

The antibody according to claim 1, wherein the antibody is chimeric antibody or humanized antibody.

### Claim 5 (depends on 1)

The antibody according to claim 1, wherein the antibody is a monoclonal antibody.

### Claim 6 (depends on 1)

The antibody according to claim 1, wherein the antibody modulates the differentiation of dendritic cells via binding ICAM-1.

### Claim 7 (depends on 1)

The antibody according to claim 1, wherein the antibody is MD-2 (accession number of KCRF-BP-00198).

### Claim 8 (depends on 1)

The antibody according to claim 1, wherein the antibody is a chimeric or humanized form of MD-2 (accession number of KCRF-BP-00198).

### Claim 9

An antibody binding to human ICAM-1 comprising a heavy chain and a light chain, the heavy chain comprising three CDRs from the heavy chain of an antibody produced by a hybridoma deposited as an accession number of KCLRF-BP-00198 and the light chain comprising three CDRs from the light chain of an antibody produced by a hybridoma deposited as an accession number of KCLRF-BP-00198.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising the antibody of claim 1.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the antibody is in isolated form.

### Claim 12 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the antibody is chimeric antibody or humanized antibody.

### Claim 13 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the antibody is a monoclonal antibody.

### Claim 14 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the antibody modulates the differentiation of dendritic cells via binding ICAM-1.

### Claim 15 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the antibody suppresses rejection of transplanted cells or organs, or suppresses graft versus host disease by transplanted hematopoietic cells.

### Claim 16

A pharmaceutical composition comprising an antibody binding to human ICAM-1 comprising a heavy chain and a light chain, the heavy chain comprising three CDRs from the heavy chain of an antibody produced by a hybridoma deposited as an accession number of KCLRF-BP-00198 and the light chain comprising three CDRs from the light chain of an antibody produced by a hybridoma deposited as an accession number of KCLRF-BP-00198.

### Claim 17 (depends on 16)

The pharmaceutical composition according to claim 16, wherein the antibody suppresses rejection of transplanted cells or organs, or suppresses graft versus host disease by transplanted hematopoietic cells.

### Claim 18

A hybridoma producing an antibody that wherein the antibody binds to domain 1 of human intercellular adhesion molecules-1 (ICAM-1), which is deposited as an accession number of KCLRF-BP-00198.

### Claim 19 (depends on 18)

The hybridoma according to claim 18, wherein the antibody binds to human intercellular adhesion molecules-1 (ICAM-1) without inhibiting binding of human ICAM-1 to human leukocyte function antigen-1 (LFA-1).
